NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
SparingVision Presents Additional Data on its Breakthrough Gene Therapy Approach SPVN06 at ASGCT 2022<
19 May 2022

SparingVision Presents Additional Data on its Breakthrough Gene Therapy Approach SPVN06 at ASGCT 2022

Findings provide additional preclinical validation ahead of IND/CTA submission planned in Q3 2022
LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results<
17 May 2022

LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results

• LAVA-1207 Phase 1/2a trial in metastatic castration-resistant prostate cancer dosed the first patients and is on track to report initial data in H2 2022
Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights<
12 May 2022

Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

We continue to advance the AU-011 overall development program and look forward to several upcoming clinical milestones, in the second half of this year
LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematologic Malignancies<
12 May 2022

LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematologic Malignancies

Supported by encouraging preclinical and preliminary clinical data, we believe in the potential of LAVA-051 to address unmet patient needs.
CVRx® Receives MR-Conditional Labeling Approval for its Barostim™ Heart Failure System<
10 May 2022

CVRx® Receives MR-Conditional Labeling Approval for its Barostim™ Heart Failure System

Heart failure patients implanted with Barostim can now receive conditional MRI scans
LAVA Therapeutics to Participate at the UBS Global Healthcare Conference<
05 May 2022

LAVA Therapeutics to Participate at the UBS Global Healthcare Conference

Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer
SparingVision Presents Progress of its Lead Gene Therapy Program, SPVN06, at ARVO 2022<
05 May 2022

SparingVision Presents Progress of its Lead Gene Therapy Program, SPVN06, at ARVO 2022

demonstrating a highly significant protection of visual function as well as greater cone density following subretinal administration of SPVN06 in a murine model.
Kala Pharmaceuticals Announces New Commercial and Medicare Coverage for EYSUVIS®<
03 May 2022

Kala Pharmaceuticals Announces New Commercial and Medicare Coverage for EYSUVIS®

Expands Commercial coverage to 92% of total commercial lives
SparingVision announces Oral Presentation of SPVN06 Data at ASGCT 2022<
03 May 2022

SparingVision announces Oral Presentation of SPVN06 Data at ASGCT 2022

SparingVision, will present pharmacology and safety data on its lead product SPVN06
Aura Biosciences Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting<
03 May 2022

Aura Biosciences Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting

Preclinical studies support further development of AU-011 for choroidal metastasis

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.